Dual HER2 inhibition with pyrotinib-trastuzumab-docetaxel confers survival benefits in untreated HER2+ metastatic BCNovember 14, 2023Breast Cancer
Obesity is a risk factor for recurrence in aromatase inhibitor-treated HR+ BCNovember 14, 2023Breast Cancer
Oncology PracticeAn 88-year-old Black woman presented with 3 months duration of asymptomatic, violaceous patches on the left breastNovember 9, 2023Breast CancerSarcoma & GIST
Oncology PracticeParticulate pollution increases the risk for breast cancerNovember 9, 2023Breast Cancer
Oncology PracticeLow vitamin D linked to paclitaxel-induced peripheral neuropathyNovember 8, 2023Breast CancerPatient & Survivor Care
Oncology PracticeT-DXd benefits persist for HER2-low breast cancerNovember 8, 2023Breast CancerPatient & Survivor Care
Oncology PracticeOmitting surgery may be safe in early BC after neoadjuvant pCRNovember 2, 2023Breast CancerPatient & Survivor Care
Commentary: Axillary Surgery, PM2.5, and Treatment With Tucatinib in Breast Cancer, November 2023October 27, 2023Breast Cancer
Oncology PracticeDato-DXd trumps chemo in advanced HR+/HER2– breast cancerOctober 25, 2023Breast CancerMetastatic Breast Cancer
Oncology PracticeThe sobering facts about alcohol and cancerOctober 25, 2023Patient & Survivor CareMixed TopicsBreast Cancer
Oncology PracticeICIs improve pCR rates in early ER+/HER2– breast cancerOctober 22, 2023Breast CancerPatient & Survivor Care
